110395 ⎘
Reverse transcribing RNA viruses; Details; Retroviridae; Human Immunodeficiency Virus, HIV Virus like particles [VLP]
Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides and Transgenes
#2HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE
#3HIV Immunogens, Vaccines, and Methods Related Thereto
#4DELIVERY OF HETEROLOGOUS PROTEINS
#5COMPOSITIONS OF NUCLEIC ACID NANOSTRUCTURES FOR VACCINES AND METHODS OF USE THEREOF
#6PSEUDOTYPED LENTIVIRAL VECTORS
#7SYNCITIN-1 FUSION PROTEINS AND USES THEREOF FOR CARGO DELIVERY INTO TARGET CELLS
#8HIV VACCINE IMMUNOGENS
#9GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE
#10LENTIVIRUS-DERIVED NANOPARTICLES COMPRISING CRISPR/CAS9 RIBONUCLEOPROTEIN COMPLEXES
#11VIRAL ANTIGEN DISPLAY COMPOSITIONS AND METHODS
#12DIFFERENTIAL CXCR4 EXPRESSION ON HEMATOPOIETIC PROGENITOR CELLS VERSUS STEM CELLS DIRECTS HOMING AND LONG-TERM ENGRAFTMENT
#13VLP-based bivalent Ebola vaccines and methods of making and using same
#14COMPOSITIONS AND METHODS FOR DELIVERING CARGO TO A TARGET CELL
#15HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE
#16Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus
#17CHIMERIC HIV VIRUS-LIKE PARTICLES
#18ENGINEERED BACTERIOPHAGE T4 NANOPARTICLES AS A POTENTIAL TARGETED ACTIVATOR OF HIV-1 LATENCY IN CD4+ HUMAN T-CELLS
#19COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF CRISPR-CAS EFFECTOR POLYPEPTIDES AND TRANSGENES
#20AFFINITY-BASED MULTIPLEXING FOR LIVE-CELL MONITORING OF COMPLEX CELL POPULATIONS
#21VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF
#22Glycan-masked engineered outer domains of HIV-1 gp120 and their use
#23Multivalent HIV vaccine boost compositions and methods of use
#24USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES
#25HIV vaccine immunogens
#26VLP-based bivalent ebola vaccines and methods of making and using same
#27VIRUS-LIKE PARTICLES WHICH CAN BE USED IN THE TREATMENT OF ALLERGIES
#28Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
#29Ebola virus and Marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches
#30Scaffolded HIV-1 Env GP140 trimer immunogen
#31VIRUS LIKE PARTICLE PRODUCTION IN PLANTS
#32INHIBITORS OF PLA2-G1B COFACTORS FOR TREATING CANCER
#33Virus-like particles which can be used in the treatment of autoimmune diseases
#34Virus-like particle (VLP) based small molecule-protein interaction trap
#35HIV-1 Env fusion peptide immunogens and their use
#36Glycan-masked engineered outer domains of HIV-1 gp120 and their use
#37VLP-BASED MONOVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME
#38VLP-based bivalent Ebola vaccines and methods of making and using same
#39Particle for the encapsidation of a genome engineering system
#40Method for detecting protein-protein interactions in a cell utilizing particle-forming polypeptide-bait fusion proteins and virus-like particles
#41Virus-like particle (VLP) based small molecule-protein interaction trap
#42Virus-like particles with high-density coating for inducing the expression of antibodies
#43Viral particle for the transfer of RNAs, especially into cells involved in immune response
#44Scaffolded HIV-1 vaccine immunogens
#45Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-1
#46Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
#47Recombinant bovine immunodeficiency virus gag virus-like particles containing influenza immunogens
#48METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING IMMUNE RESPONSE
#49Lentiviral protein delivery system for RNA-guided genome editing
#50Virus-like particles
#51Constructs for continuous monitoring of live cells
#52Virus-like particle (VLP) based small molecule-protein interaction trap
#53Methods and compositions for assessing viral nuclear localization
#54Fusion proteins and uses thereof
#55Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
#56Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
#57Lentiviral vector based immunological compounds against malaria
#58HIV therapeutics and methods of making and using same
#59Virus-like particles, methods of preparation, and immunogenic compositions
#60Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins
#61Lentiviral vector based immunological compounds against malaria
#62EXPRESSION OF HIV POLYPEPTIDES AND PRODUCTION OF VIRUS-LIKE PARTICLES
#63Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
#64Non-Integrating Retroviral Vector Vaccines
#65Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41
#66Hepatitis B virus compositions and methods of use
#67Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
#68Fusion Protein Delivery System and Uses Thereof
#69Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
#70Expression of HIV polypeptides and production of virus-like particles
#71Virus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes
#72CHRONIC PATHOGEN-EXPRESSING CELL LINES
#73MODIFIED HIV ENV POLYPEPTIDES
#74Coiled-coil lipopeptide helical bundles and synthetic virus-like particles
#75Modified HIV Env polypeptides
#76MEDICAL TREATMENT DEVICE FOR TREATING AIDS BY UTILIZING MODIFIED HUMAN IMMUNODEFICIENCY VIRUS VIRIONS TO INSERT ANTI-VIRAL MEDICATIONS INTO T-HELPER CELLS
#77Scientifically Modulated And Reprogrammed Treatment (SMART) Virus Technology Intended to Neutralize the Human Immunodeficiency Virus
#78Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
#79Protein Delivery System
#80Expression of HIV polypeptides and production of virus-like particles
#81Fusion protein delivery system and uses thereof
#82Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
#83Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use
#84Encapsidation System for Production of Recombinant Virus-Like Particles
#85Retrovirus-like particles and retroviral vaccines
#86Viral deconstruction through capsid assembly in vitro
#87Virus-like particles, methods of preparation, and immunogenic compositions
#88Stabilized viral envelope proteins and uses thereof
#89Virus-like particles, methods of preparation, and immunogenic compositions
#90Viral vectors
#91Retrovirus-like particles made non-infectious by a plurality of mutations
#92Recombinant lentivirus encoding modified GP 120 signal sequences
#93Chimeric ebola virus envelopes and uses therefor
#94Compositions and methods for the modulation of viral maturation
#95Chronic pathogen-expressing cell lines
#96Fusion protein delivery system and uses thereof